Who
Michael R. Megna
Chief Accounting Officer
Company insider
Files Form 4 as: Chief Accounting Officer, Kiniksa Pharmaceuticals International; Chief Accounting Officer, Biosphere Medical.
In numbers
- Trades disclosed
- 219
- Buys
- 0
- Sells
- 14
- Bought
- $0
- Sold
- $6.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 24 Feb 2010
- Last trade
- 3 Sep 2026
- Last filed
- 3 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Sold | $369K4,600 at $80.30 | filing |
| 3 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Sold | $369K4,600 at $80.30 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,644 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,362 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,558 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,932 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —3,932 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,558 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,650 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —14,600 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,644 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,362 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —2,558 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code M | —3,932 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,362 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —2,644 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code F | $438K5,531 at $79.28 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —3,650 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals Internationaloption or derivative · Biotechnology | SEC FORM 4 Code A | —14,600 at $0.00 | filing |
| 1 Sep 2026filed 3 Sep 2026 | KNSA Kiniksa Pharmaceuticals InternationalBiotechnology | SEC FORM 4 Code M | —3,932 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)KNSA · themarketsdaily.com · 18 Oct 2026
0 headlines in the last 90 days name Michael R. Megna; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.